Current methods to differentiate cardiomyocytes from human pluripotent stem cells (PSCs)
inadequately recapitulate complete development and result in PSC-derived cardiomyocytes …

Human pluripotent stem cells derived cardiomyocytes (PSC‐CMs) have been widely used
for disease modeling, drug safety screening, and preclinical cell therapy to regenerate …

Cardiomyocytes from human pluripotent stem cells (hPSCs-CMs) could revolutionise
biomedicine. Global burden of heart failure will soon reach USD $90 bn, while unexpected …

Pluripotent stem cells (PSCs) can undergo unlimited self-renewal and can differentiate into
all the cell types present in our body, including cardiomyocytes. Therefore, PSCs can be an …

Human pluripotent stem cell-derived cardiomyocytes (hPS-CM) may offer a number of
advantages over previous cardiac models, however, questions of their immaturity complicate …

Alterations in energy metabolism play a major role in the lineage of cardiomyocytes, such as
the dramatic changes that occur in the transition from neonate to newborn. As …

A primary limitation in the use of pluripotent stem cell‐derived cardiomyocytes (PSC‐CMs)
for both patient health and scientific investigation is the failure of these cells to achieve full …

The ability of human pluripotent stem cells (hPSCs) to differentiate into any cell type of the
three germ layers makes them a very promising cell source for multiple purposes, including …

Compact cardiomyocytes that make up the ventricular wall of the adult heart represent an
important therapeutic target population for modeling and treating cardiovascular diseases …

Maturation is the last phase of heart development that prepares the organ for strong,
efficient, and persistent pumping throughout the mammal's lifespan. This process is …